Navigation Links
Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
Date:10/27/2010

>-positive advanced NSCLC treated with a dose of 250 mg twice daily.(1)

Crizotinib (PF-02341066) is a first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK.(4)  ALK is believed to be a tumor-exclusive target that is a key driver of oncogenesis, or tumor development.(5)  Approximately 3-5 percent of NSCLC tumors are ALK-positive.(4)

"The development of crizotinib is a testament to the benefits of collaboration and partnership, between industry and academia, with investigators from all over the world, including the United States, Japan, Korea and Australia, working together with the goal of discovering a more effective treatment for advanced NSCLC patients with few other options," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit.  "While this is a Phase 1 study, the high response rates observed in patients with ALK+ NSCLC who received crizotinib suggest that we may be one step closer to the development of "precision" or "personalized" cancer treatments that target specific genetic factors that drive certain tumors."

Pfizer is continuing to study crizotinib (PF-02341066) in an ongoing clinical development program,(6,7) and plans to submit crizotinib (PF-02341066) data in the first half of next year to the U.S. Food and Drug Administration (FDA) for regulatory review.  

Additional trials of crizotinib (PF-02341066) include a randomized, Phase 3 open-label study, PROFILE 1007 (A8081007), evaluating the safety and anti-tumor activity of crizotinib (PF-02341066) versus standard of care chemotherapy in patients with previously treated ALK-positive advanced NSCLC.(5)  PROFILE 1005 (A8081005) is a Phase 2 open-label, single-arm study of efficacy and safety of crizotinib (PF-02341066) in patients with ALK-positive advanced NSCLC who have received more than one line of prior chemotherapy.(6)

For more inf
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... 2014  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), ... as XIAFLEX ® in the U.S. and XIAPEX ® ... Tom Wegman , will present a corporate overview at the ... Conference. The presentation will take place on ... Millennium Broadway Hotel in New York, NY ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... hat Pharma IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, ... abdeckt. Die interaktive PDF, verfügbar unter pharmaserialisation.com ... an dem sie jeweils in Kraft treten. ... der Serialisierung nicht länger um das "ob", sondern ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
... May 20 BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: ... treatment in the Phase 1 clinical study of ... of,phenylketonuria (PKU). The study is expected to conclude ... are dedicated to serving the PKU community and ...
... Claims Suggests a Benefit,of Anti-Tumor Necrosis Factor Therapies on Absenteeism Among ... ... Data from a new analysis of the,Active Ulcerative Colitis Trials (ACT ... percent of patients with moderately to severely active,ulcerative colitis (UC) receiving ...
Cached Medicine Technology:BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU 2BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8
(Date:9/20/2014)... September 20, 2014 The excitement is building up ... Airy, North Carolina. This year the Surry Arts Council will ... from around the country who are still fans of the Andy ... a sitcom that aired on CBS from 1960 through 1968. ... in American television history. Mount Airy, North Carolina is where ...
(Date:9/20/2014)... 20, 2014 Recently, UWDress.com, an innovative ... women’s special occasion outfits, has launched a special offer ... prom outfits are popular among worldwide clients. Now, all ... prom dresses on its website. , Additionally, ... from around the world. Great custom made items can ...
(Date:9/20/2014)... Wisconsin (PRWEB) September 20, 2014 QueenBeeTickets.com ... the young star’s tour performances. She will visit many ... of February until the 16th of April. , ... Grande Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s ... opportunity to see their favorite young singer in a ...
(Date:9/20/2014)... The Arizona Advanced Manufacturing Institute ... Manufacturing Day by opening its doors to the community. ... manufacturing labs will be offered between 10 a.m. and ... and Dobson campus (1833 W. Southern Ave, Mesa, AZ ... The AzAMI at MCC was established in the fall ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 MarijuanaDoctors.com ... successful showing at the PAIN Week conference that ... Hotel and Casino in Las Vegas from September ... primarily attended PAIN Week in the hopes of ... a viable and legitimate tool to treat chronic ...
Breaking Medicine News(10 mins):Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2
... 1 As the economic crisis deepens, SilverCensus.com ... a national web site for caregivers, senior citizens, ... urging American Veterans to investigate and take advantage ... called "Aid and Attendance." ...
... Mass., April 1, EnVivo Pharmaceuticals today ... Corporation (MTPC) for the development and commercialization ... Japan and several other Asian countries. EVP-6124 ... agonist currently in development for cognition enhancement ...
... Laboratories, Inc. Immunotech Laboratories announces successful Participation in ... its abstract " Irreversible Pepsin Fraction (IPF) displays ... in vitro investigation of activity on human lymphocytes." ... Conference on Clinical and Social Research on AIDS ...
... worse cholesterol, blood vessel health than with South Beach, Ornish ... the "maintenance" phase that occurs after initial weight loss, the ... on the heart than the high-fat, low-carbohydrate Atkins regimen, a ... diets to see which might be better at achieving weight ...
... April 1 Harvest Technologies Corp. ... study report was completed for the first thirty (30) ... non-reconstructable critical limb ischemia due to advanced thromboangitis obliterans, ... is being conducted at Sri Ramachandra University in Chennai ...
... VC Business Practices to Funding ResearchTUCSON, Ariz., April 1 ... launch of a new initiative, MDA Venture Philanthropy (MVP), ... A 501(c)(3) nonprofit organization, MVP will break with traditional ... of venture capital firms to fast track the development ...
Cached Medicine News:Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 2Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 3Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 2Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 3Health News:Beating a Global Killer: HIV/AIDS 2Health News:Beating a Global Killer: HIV/AIDS 3Health News:Beating a Global Killer: HIV/AIDS 4Health News:Atkins Diet Tougher on Heart After Weight Loss 2Health News:Atkins Diet Tougher on Heart After Weight Loss 3Health News:Harvest Technologies Announces Interim Study Results From Critical Limb Ischemia Trial in Chennai India 2Health News:Harvest Technologies Announces Interim Study Results From Critical Limb Ischemia Trial in Chennai India 3Health News:Muscular Dystrophy Association Launches New Venture Philanthropy 2Health News:Muscular Dystrophy Association Launches New Venture Philanthropy 3
Delicate membrane hook/pick with hook on side of instrument for engaging membranes. 20 gauge shaft with balanced titanium handle. Dark finish for reduced glare. Right....
0.5 mm angled tip. Round knurled handle with dull finish. Tip angle: 130 degrees....
Teardrop shape tip with post. Round knurled handle with dull finish....
Excellent for manipulation of the intraocular lens in the capsular bag. The angled and curved shaft allows the instrument to reach across the implant and catch the optic/ haptic junction to facilitat...
Medicine Products: